ALKS
Alkermes Inc. plcstockNASDAQ
alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (cns) diseases. the company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. headquartered in dublin, ireland, alkermes plc has an r&d center in waltham, massachusetts; a research and manufacturing facility in athlone, ireland; and a manufacturing facility in wilmington, ohio. for more information, please visit alkermes' website at www.alkermes.com.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 47.03 | 2026-11-13 | -1.76% | 2.125 |
| 1M | 44.11 | 2026-10-20 | +4.74% | 0.680 |
| 3M | 48.02 | 2026-08-20 | -3.79% | 0.709 |
| 6M | 36.98 | 2026-05-20 | +24.93% | 0.479 |
| 1Y | 28.19 | 2025-11-20 | +63.89% | 0.808 |
| 2Y | 27.91 | 2024-11-20 | +65.53% | — |
| 5Y | 23.24 | 2021-11-19 | +98.80% | 0.593 |
Alkermes Inc. plc (NASDAQ:ALKS) stock price today is $46.20, and today's volume is 1,406,379. ALKS is down 1.387% today. The 30 day average volume is 1.71M. ALKS market cap is $7.76B with 168.04M shares outstanding.
